Gilead’s Use Of Patents For $10B Tax Dodge Could Ignite Move For Policy Change

Gilead is the US company whose use of patents to charge $1000 per pill for a hepatitis C medicine in the United States helped make high drug prices a developed country household issue and fodder for elected officials seeking change. Now the company has come under further fire after being found to have moved some US$10 billion overseas to avoid US taxes - even after having received US taxpayer support for its activities - which it orchestrated by moving its patent rights overseas. A new report detailing the company's tax dodge includes a proposal for a way to clamp down on this type of patent activity.








